Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the estimated 360,000 survivors of childhood cancer experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children?s Oncology Group (COG), the world?s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 17 years ago. The COG?s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children?s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute?s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life children with cancer and survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, the COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Statistics and Data Management Center which collaborates with COG scientific leaders to design, conduct, analyze and report the results of clinical-translational trials for the treatment of childhood cancers.

Public Health Relevance

The Children?s Oncology Group (COG) is the world?s largest organization devoted exclusively to childhood and adolescent cancer research. Over 220 leading children?s hospitals, universities, and cancer centers across US, Canada and other countries participate in COG research, which is focused on developing better treatments that can improve the cure rate and outcome for all children with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Public Health Institute
United States
Zip Code
Marks, Lianna J; McCarten, Kathleen M; Pei, Qinglin et al. (2018) Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol. Blood 132:1208-1211
Ehrlich, Peter F (2018) Reply to: Synoptic operative reports for quality improvement in pediatric cancer care: Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:e27277
Ozkaynak, M Fevzi; Gilman, Andrew L; London, Wendy B et al. (2018) Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol 9:1641
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Stockard, Bradley; Garrett, Timothy; Guingab-Cagmat, Joy et al. (2018) Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. Sci Rep 8:5534
Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261
Niemas-Teshiba, Risa; Matsuno, Ryosuke; Wang, Larry L et al. (2018) MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget 9:6416-6432
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Aldrink, Jennifer H; Appel, Burton; Kaplan, Joel A et al. (2018) Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. J Pediatr Hematol Oncol 40:246-247
Burke, Michael J; Devidas, Meenakshi; Maloney, Kelly et al. (2018) Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 59:1624-1633

Showing the most recent 10 out of 317 publications